Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C25H35NO5 |
| Molecular Weight | 429.5501 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CCCCOC(=O)c1ccc(c(c1)OC)OC)C(C)Cc2ccc(cc2)OC
InChI
InChIKey=VYVKHNNGDFVQGA-UHFFFAOYSA-N
InChI=1S/C25H35NO5/c1-6-26(19(2)17-20-9-12-22(28-3)13-10-20)15-7-8-16-31-25(27)21-11-14-23(29-4)24(18-21)30-5/h9-14,18-19H,6-8,15-17H2,1-5H3
DescriptionCurator's Comment:: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con744437.pdf | https://www.ncbi.nlm.nih.gov/pubmed/20128021
Curator's Comment:: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con744437.pdf | https://www.ncbi.nlm.nih.gov/pubmed/20128021
Mebeverine is an antispasmodic with a direct action on the smooth muscle of the gastrointestinal tract. The exact mechanism of action is not known, but multiple mechanisms, such as a decrease in ion channel permeabilities, blockade of noradrenaline reuptake, a local anesthetic effects, as well as weak anti-muscarinic and phosphodiesterase inhibitory effect might contribute to the local effects of Mebeverine. This medicine is used to treat symptoms of irritable bowel syndrome (IBS) and similar problems such as chronic irritable colon, spastic constipation, mucous colitis and spastic colitis. Most people will not have problems with Mebeverine, but some may get some side effects, such as: difficulty in breathing, swelling of face, neck, tongue or throat, skin rash, red itchy skin.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Alpha-1 adrenergic receptor (guinea pig) |
|||
Target ID: Muscarinic acetylcholine receptors (guinea pig) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | Colofac Approved UseColofac is used to treat symptoms of irritable bowel syndrome and similar problems. Launch Date258595200000 |
|||
| Palliative | Colofac Approved UseThis medicine is used to treat symptoms of irritable bowel syndrome (IBS) and similar problems such as chronic irritable colon, spastic constipation, mucous colitis and spastic colitis. Launch Date258595200000 |
|||
| Palliative | Colofac Approved UseThis medicine is used to treat symptoms of irritable bowel syndrome (IBS) and similar problems such as chronic irritable colon, spastic constipation, mucous colitis and spastic colitis Launch Date258595200000 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The antispasmodic drug mebeverine leads to positive amphetamine results by fluorescence polarization immunoassay (FPIA)--studies on the toxicological analysis of urine by FPIA and GC-MS. | 2001 Jul-Aug |
|
| [Mebeverine-retard in relief of pain in gallstone patients]. | 2002 |
|
| Identification of mebeverine acid as the main circulating metabolite of mebeverine in man. | 2002 Jun 20 |
|
| Spectrophotometric microdetermination of nefopam, mebevrine and phenylpropanolamine hydrochloride in pharmaceutical formulations using alizarins. | 2004 Jul |
|
| Treatment patterns and health care costs of mebeverine-treated IBS patients: a case-control study. | 2004 Nov |
|
| Rapid accurate mass desorption electrospray ionisation tandem mass spectrometry of pharmaceutical samples. | 2005 |
|
| A new RP-HPLC method for analysis of mebeverine hydrochloride in raw materials and tablets. | 2005 Apr |
|
| [Mebeverine for complex treatment of opisthorchiasis]. | 2006 |
|
| [The pain problem as a historic aspect. Pain at the biliary pathology. Mebeverine hydrochloride as a part of complex therapy]. | 2006 |
|
| Generic and brand-name drugs. Are different criteria sufficiently taken into account before granting market authorisation? | 2006 |
|
| Formulation of an antispasmodic drug as a topical local anesthetic. | 2006 Dec 1 |
|
| A validated chiral HPLC method for the determination of mebeverine HCl enantiomers in pharmaceutical dosage forms and spiked rat plasma. | 2006 Feb |
|
| Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial. | 2006 Jun |
|
| Investigative implications of the instability and metabolism of mebeverine. | 2006 Mar |
|
| Quality of life of patients with irritable bowel syndrome is low compared to others with chronic diseases. | 2006 May |
|
| "My patients are the sickest". | 2006 May |
|
| Mebeverine influences sodium ion transport in the distal colon. | 2006 Sep-Oct |
|
| [Chronic abdominal pain syndrome in biliary pathology]. | 2007 |
|
| [Assessment of the efficacy of mebeverine in the complex therapy of chronic noncalculolis cholecystitis and biliary dysfunction]. | 2007 |
|
| Colon-specific drug delivery for mebeverine hydrochloride. | 2007 Dec |
|
| [Drug treatment of irritable bowel syndrome: an unmet need]. | 2007 Mar |
|
| Improving the detection limits of antispasmodic drugs electrodes by using modified membrane sensors with inner solid contact. | 2007 May 9 |
|
| A novel formulation for mebeverine hydrochloride. | 2007 Oct |
|
| Health technology assessment and ill-structured problems: a case study concerning the drug mebeverine. | 2007 Summer |
|
| [Efficacy of duspatalin in the treatment and prophylaxis of postcholecystectomic syndrome]. | 2008 |
|
| Serotonin receptor modulators in the treatment of irritable bowel syndrome. | 2008 Feb |
|
| Spectrophotometric determination of benzydamine HCl, levamisole HCl and mebeverine HCl through ion-pair complex formation with methyl orange. | 2008 Mar |
|
| Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. | 2008 May |
|
| Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. | 2008 Nov 13 |
|
| Drug use in children: cohort study in three European countries. | 2008 Nov 24 |
|
| Development of membrane selective electrode for determination of the antipsychotic sulpiride in pharmaceuticals and urine. | 2009 |
|
| [The effectiveness of spasmolytic therapy in chronic acalculous cholecystitis]. | 2009 |
|
| Psychological associations of irritable bowel syndrome besides panic disorder: an often overlooked reality. | 2009 |
|
| Validated LC-MS/MS method for determination of Alverine and one of its hydroxy metabolites in human plasma along with its application to a bioequivalence study. | 2009 Jan 15 |
|
| pH-Sensitive Mebeverine Microspheres for Colon Delivery. | 2009 Jul |
|
| The four killers of Meckel's diverticulum. | 2009 May |
|
| [A method for non-medicamentous treatment of irritated bowel syndrome]. | 2009 May-Jun |
|
| [Modern approaches to the therapy of biliary system diseases]. | 2010 |
|
| Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
| Validated HPLC determination of the two fixed dose combinations (chlordiazepoxide hydrochloride and mebeverine hydrochloride; carvedilol and hydrochlorothiazide) in their tablets. | 2010 Jul-Aug |
|
| Design and formulation of mebeverine HCl semisolid formulations for intraorally administration. | 2010 Mar |
|
| Colloids as a sink for certain pharmaceuticals in the aquatic environment. | 2010 May |
|
| First derivative synchronous fluorescence spectroscopy for the simultaneous determination of sulpiride and mebeverine hydrochloride in their combined tablets and application to real human plasma. | 2010 Nov |
|
| Management of irritable bowel syndrome in primary care: feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy website. (MIBS trial). | 2010 Nov 18 |
|
| Topical piroxicam in vitro release and in vivo anti-inflammatory and analgesic effects from palm oil esters-based nanocream. | 2010 Nov 4 |
|
| Development and validation of stability indicating HPLC and HPTLC methods for determination of sulpiride and mebeverine hydrochloride in combination. | 2010 Sep |
|
| Autoimmune hepatitis triggered by nitrofurantoin: a case series. | 2010 Sep 23 |
|
| Presentations of perforated colonic pathology in patients with polymyalgia rheumatica: two case reports. | 2010 Sep 6 |
|
| Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
Patents
Sample Use Guides
One tablet (135 mg) three times a day. This may be gradually reduced after a few weeks when the desired effect has been obtained. The tablets are best taken 20 minutes before meals.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C66880
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
||
|
WHO-ATC |
A03AA04
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
||
|
WHO-VATC |
QA03AA04
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3625-06-7
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY | |||
|
7F80CC3NNV
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY | |||
|
1642
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY | |||
|
3625-06-7
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY | |||
|
29410
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY | RxNorm | ||
|
4031
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY | |||
|
222-830-4
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY | |||
|
CHEMBL282121
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY | |||
|
SUB08662MIG
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY | |||
|
M7108
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY | Merck Index | ||
|
C005096
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY | |||
|
MEBEVERINE
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY | |||
|
1191
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY | |||
|
DB12554
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY | |||
|
C83909
Created by
admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
